Acta Biomaterialia, Journal Year: 2024, Volume and Issue: unknown
Published: Dec. 1, 2024
Language: Английский
Acta Biomaterialia, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 1, 2025
Language: Английский
Citations
2
Biomaterials, Journal Year: 2024, Volume and Issue: 306, P. 122480 - 122480
Published: Jan. 21, 2024
Language: Английский
Citations
11
Biomaterials, Journal Year: 2024, Volume and Issue: 312, P. 122745 - 122745
Published: Aug. 3, 2024
Language: Английский
Citations
9
International Journal of Pharmaceutics, Journal Year: 2024, Volume and Issue: 656, P. 124045 - 124045
Published: March 30, 2024
Language: Английский
Citations
7
Advanced NanoBiomed Research, Journal Year: 2024, Volume and Issue: 4(4)
Published: Jan. 26, 2024
This review is aiming to systematically elucidate the unique role of nanotechnology in optimizing therapeutic modalities for combinatorial cancer immunotherapy, which enables synergistic integration multiple treatment strategies. In particular, has enabled combination immunotherapy with physical therapies, chemotherapy, metal therapy, and nucleic acid therapy. each regimen, nanocarriers play multifaceted roles by achieving targeted codelivery different therapeutics individual modality. offers new paradigms guide precision medicine treatment. Immunotherapy alone unlikely achieve personalized cancer, are needed future. To overcome technical bottlenecks realize precise regulation tumor microenvironment treatment, it crucial develop novel nanosystems integrated sensing, targeting, functionalities.
Language: Английский
Citations
6
Molecules, Journal Year: 2024, Volume and Issue: 29(18), P. 4405 - 4405
Published: Sept. 16, 2024
Hepatocellular carcinoma (HCC) ranks among the most prevalent malignant tumors, exhibiting a high incidence rate that presents substantial threat to human health. The use of sorafenib and lenvatinib, commonly employed as single-agent targeted inhibitors, complicates treatment process due absence definitive targeting. Nevertheless, advent nanotechnology has injected new optimism into domain liver cancer therapy. Nanocarriers equipped with active targeting or passive mechanisms have demonstrated capability deliver drugs tumor cells efficiency. This approach not only facilitates precise delivery affected site but also enables drug release, thereby enhancing therapeutic efficacy. As medical technology progresses, there is an increasing call for innovative modalities, including novel chemotherapeutic agents, gene therapy, phototherapy, immunotherapy, combinatorial treatments HCC. These emerging therapies are anticipated yield improved clinical outcomes patients, while minimizing systemic toxicity adverse effects. Consequently, application poised significantly improve HCC treatment. review focused on strategies in this area.
Language: Английский
Citations
4
ACS Applied Materials & Interfaces, Journal Year: 2025, Volume and Issue: unknown
Published: April 9, 2025
As a promising candidate in overcoming resistance, providing synergy, and developing treatments, conjugated combination drugs mostly prevail over drug cocktails establishing prodrugs precisely codelivering multiple for chemotherapies. However, current drug-drug conjugation methods (e.g., esterification, amidation, etherification, etc.) do not allow quantitative conversion require necessary purification of crude products, resulting limited economy initial drugs. Meanwhile, practical stimulus concentration vivo usually fails to efficiently activate parent release from conjugates target sites, which diminishes their efficacy. Herein, we report click strategy based on boronic acid-cis diol complexation, realizing fast (<30 min), quantitative, purification-free bortezomib (BTZ) azacytidine (AZA) or capecitabine doxifluridine. Notably, the BTZ-AZA conjugate spontaneously self-assembles into nanomedicine exhibits enhanced synergistic Furthermore, BTZ AZA could be polyprodrug with controlled size composition, different organelle uptakes augment synergy by approximately 1000-fold versus free toward A549 adenocarcinoma cells (IC50: 0.55 nM 536.7 nM). This would expand vision smart
Language: Английский
Citations
0
Journal of Nanobiotechnology, Journal Year: 2025, Volume and Issue: 23(1)
Published: April 26, 2025
Language: Английский
Citations
0
ACS Applied Nano Materials, Journal Year: 2024, Volume and Issue: 7(7), P. 7966 - 7977
Published: April 1, 2024
Effective therapeutic approaches against head and neck squamous cell carcinoma (HNSCC), which is a prevalent malignant tumor, are currently lacking. Although immunotherapy has emerged as promising strategy for treating HNSCC, its efficacy severely limited by the immunosuppressive tumor microenvironment. Self-delivery nanoparticles, comprising Toll-like receptor (TLR) agonists photosensitizers, were successfully developed to address this challenge in combinatorial HNSCC treatment. After intravenous administration, these nanoparticles efficiently accumulated tumors, enhancing bioavailability of agonist triggering TLR signaling pathway remodel Simultaneously, photosensitizers induced immunogenic death activated stimulator interferon gene (STING) cells via photodynamic therapy. The development tumors was significantly inhibited antitumor immunity nanoparticles. This study provided new paradigm immunotherapy, involving synergistic regulation immune microenvironment with
Language: Английский
Citations
3
Nanoscale, Journal Year: 2024, Volume and Issue: 16(31), P. 14734 - 14747
Published: Jan. 1, 2024
A small-molecule nanomedicine with high drug loading, robust stability, responsive release and a synergistic photochemotherapeutic effect has been developed for cancer therapy. Image created Biorender.
Language: Английский
Citations
3